ArticleArchives of toxicology2022

Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.

Anselm Morell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.